Literature DB >> 7309439

Sensitivity deficits consistent with aberrant crossed visual pathways in human albinos.

R St John, B Timney.   

Abstract

There is both anatomical and electrophysiological evidence that human albinos have abnormally crossed visual pathways. The present study examined some perceptual consequences of such pathways on the visual abilities of 12 oculocutaneous albinos and one ocular albino. Measurements were made of visual fields in all subjects. For seven subjects, contrast sensitivity functions were obtained for the central, nasal, and temporal retinas. There was a wide variation in the dimensions of the visual fields, but there was no evidence for a loss corresponding to the origin of the aberrant projections. On the basis of their contrast sensitivity functions, however, it was possible to classify the albinos into two groups. One group, with higher overall sensitivity, showed no differences between central, nasal, and temporal retina. The other group showed a marked depression in sensitivity for the temporal retina, indicating that in some albinos, information from the retinal region corresponding to the aberrant pathway is degraded.

Entities:  

Mesh:

Year:  1981        PMID: 7309439

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  4 in total

1.  Albinism: a model of adaptation of the brain in congenital visual disorders.

Authors:  Irene Gottlob
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

2.  Perceptual relevance of abnormal visual field representations: static visual field perimetry in human albinism.

Authors:  Michael B Hoffmann; Petra S Seufert; Linda C Schmidtborn
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

3.  Vision in albinism.

Authors:  C G Summers
Journal:  Trans Am Ophthalmol Soc       Date:  1996

4.  Albinism in childhood: a flash VEP and ERG study.

Authors:  I Russell-Eggitt; A Kriss; D S Taylor
Journal:  Br J Ophthalmol       Date:  1990-03       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.